Analytical Protocol
High-throughput phytochemical characterization and preclinical validation pipelines calibrated to meet stringent Israeli Ministry of Health (MOH) standards and international cGMP expectations.
Israel stands out as an international hub for life sciences innovation, characterized by cutting-edge biomedical incubators around Tel Aviv, Rehovot, and Haifa, alongside world-renowned dermatological extraction industries rooted in the Dead Sea basin and the Galilee.
Known globally as the "Start-Up Nation," Israel hosts one of the highest densities of biotech and digital health ventures globally. In the domain of natural materials, Israeli academic centers such as the Weizmann Institute of Science, the Hebrew University of Jerusalem, and the Technion continually unearth sophisticated molecular mechanisms from arid flora, halophilic microorganisms, and Mediterranean botanicals.
However, Israeli domestic commercial scale is bounded by high local labor costs, strict regional water allocation, and limited agricultural square footage. As therapeutic formulations transition from exploratory academic discovery to pilot synthesis and commercial cGMP scale, domestic enterprises require offshore contract research and contract manufacturing partners capable of conducting reproducible, multi-tiered evaluations without compromising proprietary formula security.
Deploying natural materials into the Israeli commercial stream requires navigating stringent public health barriers governed by the Israel Ministry of Health (Misrad HaBriut). Botanical ingredients aimed at food supplements, foods for special medical purposes (FSMP), and topical pharmaceuticals are subject to exhaustive safety evaluations regarding toxic heavy metal contamination, residual pesticides, mycotoxin residues, and microbial bioburdens.
Additionally, commercial adoption within Israeli supermarkets, pharmacies (such as Super-Pharm and Be), and institutional hospital formularies necessitates strict Kosher certification (Kashrut), ranging from standard Rabbinate clearance to ultra-orthodox Mehadrin standards (such as Badatz Eida Charedit). Evaluation protocols must verify not only the chemical purity of the botanical isolate but also the entire synthesis line: ensuring processing aids, solvent carriers (e.g., ethanol vs. synthetic alcohols), and equipment washdown agents comply with kosher cross-contamination prohibitions.
How botanical active ingredient evaluations convert theoretical molecular structures into commercially viable, high-margin consumer and medical products across key Israeli sectors.
Israel has earned global prestige through Dead Sea dermatological skin-care formulations. Modern consumer demand, however, has transitioned from simple mineral muds to hybrid mineral-botanical synergies capable of mitigating oxidative stress, photo-aging from Mediterranean ultraviolet exposure, and chronic dermatological conditions like psoriasis and atopic dermatitis.
Evaluation Role: High-precision in vitro enzymatic inhibition testing (e.g., elastase, collagenase, and hyaluronidase inhibition assays), transdermal permeation kinetics, and 3D human reconstituted skin model irritation evaluations to substantiate anti-inflammatory and cellular repair marketing claims under EU Regulation (EC) No 1223/2009.
With rising metabolic syndrome incidences across developed nations, Israeli medical researchers focus intently on plant polyphenols, berberine analogs, and triterpenoid saponins capable of modulating AMP-activated protein kinase (AMPK) pathways and reducing postprandial glucose spikes.
Evaluation Role: Establishing comprehensive chromatographic fingerprints to verify batch stability of polyphenol compounds across different seasonal harvests, combined with in vitro alpha-glucosidase and alpha-amylase inhibitory assays, transitioning into controlled rodent pharmacokinetic (PK/PD) studies.
Israel's intense high-tech industry has catalyzed exponential domestic growth in adaptogenic dietary supplements and neuro-protective nutraceuticals designed to reduce cortisol, improve focus, and protect against neuro-inflammatory degeneration.
Evaluation Role: Quantitative LC-MS/MS potency analysis of active ginsenosides, withanolides, and bacosides, establishing stability under accelerated climatic conditions (Zone IVb: 30°C / 75% RH) to ensure bio-potency survives transport and Mediterranean shelf life.
Connect directly with our senior phytochemical team. We provide method validation protocols, LOD/LOQ determinations, and complete stability documentation suitable for Israel MOH registration dossiers.
High information gain through validated pharmacopeial protocols. Natural materials are not homogenous static compounds; their chemical profile fluctuates radically based on seasonal timing, geoclimatic conditions, and post-harvest thermal processing.
| Evaluation Phase | Analytical Technology | Target Biomarkers & Parameters | Deliverable Technical Documentation |
|---|---|---|---|
| Phase 1: Raw Origin & Seasonality Screening | HPTLC, UPLC-Q-TOF-MS, NIR Spectroscopy | Phenolic acids, alkaloid distribution, volatile terpene profiles across phenological harvest stages (flowering vs. seed maturation). | Full Chemodiversity Map, Optimal Harvest Window Determination Report, Raw Biomass Certificate of Analysis (CoA). |
| Phase 2: Extraction & Fractionation Kinetics | Dynamic Counter-Current, SFE-CO2, Macroporous Resin Adsorption | Enrichment ratio of bioactive fractions vs. ballast tannins, solvent residue thresholds (USP <467> Class 1-3 solvents). | Process Scale-Up Matrix, Critical Process Parameters (CPP) Validation Document, Solvent Recovery Feasibility File. |
| Phase 3: Assay Method Establishment | HPLC-DAD, GC-MS/MS, Triple Quad LC-MS | Resolution factor >1.5 for critical isomer pairs, linearity (R² > 0.999), precision (RSD < 2.0%), recovery accuracy (98–102%). | ICH Q2(R1) Method Validation Dossier, High-Resolution Chromatographic Fingerprint Standards, SOP Transfer Manual. |
| Phase 4: Contaminant & Toxicological Clearance | ICP-MS, LC-MS/MS Multiresidue, qPCR, Pyrogen Testing | Heavy metals (Pb, Cd, As, Hg < 0.1 ppm target), 500+ organochlorine/organophosphate pesticides, aflatoxins (B1, B2, G1, G2). | Comprehensive Safety Clearance Dossier compliant with Israeli MOH & European Pharmacopoeia (EP 2.8.13). |
| Phase 5: Preclinical In Vitro / In Vivo Validation | Cell culture bioassays, flow cytometry, ELISA, Rodent PK/PD | IC50/EC50 cytotoxicity, cytokine down-regulation (TNF-α, IL-6), acute oral toxicity (LD50), sub-chronic 90-day repeat dose safety. | GLP-compliant Preclinical Study Report, Toxicology Data Package for New Dietary Ingredient (NDI) filings. |
A plant harvested in the arid Negev basin will manifest a dramatically heightened secondary metabolite defense profile (e.g., elevated flavonoids and protective osmoprotectants) compared to the identical species cultivated in temperate river valleys. Our evaluation framework does not assume chemical parity. By profiling multi-batch samples harvested across spring, summer, and autumn from diverse microclimates, we identify the exact bio-harvest window that maximizes yield, saving up to 34% in downstream extraction raw material costs.
Inferior testing protocols rely solely on single-marker HPLC assays, leaving room for economically motivated adulteration with synthetic analogs. Our laboratories deploy full chromatographic fingerprint similarity evaluations (Chinese Pharmacopoeia and USP aligned), comparing over 20 characteristic peaks simultaneously. This ensures the total phytomedicinal matrix is conserved, maintaining genuine biological synergy and protecting our Israeli brand partners against regulatory recalls.
How our Changsha-based R&D center and state-of-the-art pilot facilities combine extensive botanical diversity, industrial economy of scale, and direct end-to-end QC execution for Israeli buyers.
China commands over 12,000 documented medicinal plant species spanning five major climatic zones. MedGence maintains long-standing Good Agricultural and Collection Practice (GACP) contract partnerships across Sichuan, Yunnan, Hunan, and Jilin provinces. This direct connection eliminates multiple layers of raw herb brokers, ensuring raw biomass arrives at our evaluation labs with zero exposure to sulfur fumigation, chemical ripening, or unregulated pesticides.
Unlike pure analytical test houses that cannot manufacture, or high-volume extraction mills that refuse customized pilot trial batches, our dual CRO/CDMO architecture accommodates dynamic order scales. Israeli startup innovators can commission an exploratory 20-kg pilot batch validated on our pilot line, evaluate market feedback in Tel Aviv clinical centers, and seamlessly scale to 50-metric-ton commercial campaigns without transferring methods to a new contract manufacturer.
Conducting comprehensive in vitro, animal toxicology, and chromatographic method development entirely within Western or Israeli domestic CROs carries astronomical cost burdens that exhaust early-stage venture funding. MedGence's centralized R&D facility in Hunan delivers 300+ career bio-scientists, advanced Shimadzu/Agilent instrumentation, and GLP-standardized testing animal vivariums at a 40–60% efficiency improvement over European laboratory tariffs.
Rigorous quality management systems that bridge Chinese high-capacity production with strict Israeli regulatory filing protocols, European export compliance, and Kosher supply chain certification.
For Israeli biotech and nutraceutical ventures whose primary company valuation is anchored in exclusive intellectual property, formula leakage is a catastrophic commercial threat. We operate strictly on an entrusted R&D model guarded by rigorous Non-Disclosure Agreements (NDAs).
Client formulations, target compound fractions, and extraction optimization parameters are sequestered on isolated local servers with biometrically restricted physical lab access. All chromatography logs, raw spectra, and extraction parameters are transferred exclusively to the client upon study finalization, guaranteeing your exclusive competitive moat remains strictly intact.
Customs clearance into the Port of Ashdod or Port of Haifa requires impeccable administrative documentation. MedGence generates audit-ready compliance packages designed specifically to accelerate clearance through Israel's customs and the Ministry of Health's Food & Drug divisions.
Select individual analytical evaluations or deploy our comprehensive lab-to-commercial manufacturing pathway for your botanical ingredient program.
Key considerations for Israeli procurement directors, chief science officers, and quality assurance leads engaging with an offshore natural medicine CRO & CDMO.